Tango Therapeutics, Inc. (TNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.52-1.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TNGX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | 62.4 | 42.1 | 36.5 | 24.9 | 37.0 | — |
| Total Revenues | — | 62.4 | 42.1 | 36.5 | 24.9 | 37.0 | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 133.6 | 132.2 | 143.9 | 115.2 | 105.9 | 77.6 | — |
| Operating Income | (136.3) | (111.3) | (145.6) | (114.2) | (111.1) | (58.2) | — |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 12.6 | 9.7 | 15.5 | 12.6 | 2.9 | 0.2 | — |
| EBT, Incl. Unusual Items | (123.8) | (101.6) | (130.1) | (101.6) | (108.1) | (57.9) | — |
| Income Tax Expense | (0.1) | 0.0 | 0.2 | 0.1 | 0.1 | 0.3 | — |
| Net Income | |||||||
| Net Income | (123.7) | (101.6) | (130.3) | (101.7) | (108.2) | (58.2) | — |
| Per Share | |||||||
| Basic EPS | (0.83) | (0.87) | (1.19) | (1.08) | (1.23) | (0.94) | — |
| Diluted EPS | (0.83) | (0.87) | (1.19) | (1.08) | (1.23) | (0.94) | — |
| Basic Weighted Avg Shares | 149.9 | 116.2 | 109.2 | 94.6 | 87.8 | 62.1 | — |
| Diluted Weighted Avg Shares | 149.9 | 116.2 | 109.2 | 94.6 | 87.8 | 62.1 | — |
| Supplemental | |||||||
| EBIT | (136.3) | (111.3) | (145.6) | (114.2) | (111.1) | (58.2) | — |
| Effective Tax Rate | 0.1% | — | — | -0.1% | -0.0% | -0.5% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.